Seizert Capital Partners LLC Has $6.24 Million Stock Position in Incyte Co. (NASDAQ:INCY)

Seizert Capital Partners LLC lifted its holdings in shares of Incyte Co. (NASDAQ:INCY) by 12.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 94,342 shares of the biopharmaceutical company’s stock after purchasing an additional 10,438 shares during the period. Seizert Capital Partners LLC’s holdings in Incyte were worth $6,236,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Avantax Advisory Services Inc. acquired a new position in Incyte during the 1st quarter worth about $254,000. Entropy Technologies LP bought a new stake in Incyte in the first quarter valued at approximately $327,000. Vanguard Group Inc. increased its position in Incyte by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 22,715,821 shares of the biopharmaceutical company’s stock valued at $1,294,120,000 after purchasing an additional 196,440 shares during the period. Edgestream Partners L.P. raised its holdings in Incyte by 1,197.0% during the 1st quarter. Edgestream Partners L.P. now owns 42,776 shares of the biopharmaceutical company’s stock worth $2,437,000 after purchasing an additional 39,478 shares during the last quarter. Finally, Jacobi Capital Management LLC bought a new position in Incyte during the 1st quarter worth approximately $447,000. Institutional investors own 96.97% of the company’s stock.

Analyst Ratings Changes

INCY has been the subject of several recent analyst reports. Wells Fargo & Company increased their price objective on shares of Incyte from $62.00 to $68.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 30th. Citigroup increased their price target on Incyte from $92.00 to $97.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Morgan Stanley lifted their price objective on Incyte from $64.00 to $69.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 30th. JMP Securities restated a “market perform” rating on shares of Incyte in a research report on Tuesday, September 17th. Finally, The Goldman Sachs Group lifted their target price on Incyte from $63.00 to $70.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Incyte currently has an average rating of “Hold” and an average target price of $77.16.

Incyte Price Performance

Shares of NASDAQ INCY opened at $75.87 on Friday. The stock has a market cap of $14.62 billion, a price-to-earnings ratio of 541.97, a PEG ratio of 8.75 and a beta of 0.71. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.82 and a current ratio of 1.87. Incyte Co. has a fifty-two week low of $50.35 and a fifty-two week high of $83.95. The firm’s 50-day simple moving average is $68.99 and its 200 day simple moving average is $63.83.

Incyte (NASDAQ:INCY) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.07 EPS for the quarter, missing the consensus estimate of $1.19 by ($0.12). The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.08 billion. Incyte had a negative return on equity of 0.63% and a net margin of 0.80%. The business’s revenue for the quarter was up 23.8% compared to the same quarter last year. During the same period last year, the company earned $0.91 earnings per share. As a group, research analysts anticipate that Incyte Co. will post 0.4 earnings per share for the current fiscal year.

Insider Activity at Incyte

In other news, EVP Barry P. Flannelly sold 3,680 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $79.68, for a total value of $293,222.40. Following the completion of the transaction, the executive vice president now directly owns 58,042 shares of the company’s stock, valued at $4,624,786.56. This represents a 5.96 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Thomas Tray sold 572 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $62.94, for a total value of $36,001.68. Following the sale, the insider now directly owns 24,825 shares of the company’s stock, valued at $1,562,485.50. The trade was a 2.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 12,702 shares of company stock valued at $856,166. 17.60% of the stock is owned by insiders.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.